

## PRESS CLIPPING SHEET

<b>PUBLICATION:</b>	Daily News (2)
<b>DATE:</b>	31-May-2018
<b>COUNTRY:</b>	Egypt
<b>CIRCULATION:</b>	80,000
<b>TITLE :</b>	Novartis Egypt announces success of new drug to slow progress of advanced breast cancer
<b>PAGE:</b>	06
<b>ARTICLE TYPE:</b>	Agency-Generated News
<b>REPORTER:</b>	Staff Report
<b>AVE:</b>	9,300

**Novartis Egypt announces success of new drug to slow progress of advanced breast cancer**  
*Announcement of Monaleesa study results*

Novartis held a press conference to announce the availability of a new drug in Egypt to treat advanced breast cancer. The results of the latest clinical experiments known as "Monaleesa" were announced. The discussion was led by Islam Anan, the CEO of Accsight and a lecturer in the economics of medicine at the Faculty of Pharmacy of Ain Shams University.

Sherif Amin, president of Novartis Oncology in Egypt, Libya, Tunisia, and Morocco, pointed out that the company's vision and commitment towards patients and healthcare providers include serious work on scientific research and producing better drugs and solutions for cancer patients. Launching this new drug

and registering it in Egypt in such a short time is a great achievement.

"We would like to thank the concerned authorities at the Ministry of Health and the Egyptian Drug Authority for their cooperation and the way they sped up the procedures, allowing the provision of the most modern treatment methods of cancer patients in Egypt. We are truly happy that the new drug has proven its effectiveness and ability to improve the quality of life of patients and reduce the pain levels. We are enthusiastic about working with various health providers to give women with advanced breast cancer some hope," he added.